Literature DB >> 14592598

Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

Philippe Eggimann1, Jorge Garbino, Didier Pittet.   

Abstract

A substantial proportion of patients become colonised with Candida spp during hospital stay, but only few subsequently develop severe infection. Clinical signs of severe infection manifest early but lack specificity until late in the course of the disease, thus representing a particular challenge for diagnosis. Mostly nosocomial, invasive candidiasis occurs in only 1-8% of patients admitted to hospitals, but in around 10% of patients housed in intensive care units where it can represent up to 15% of all nosocomial infections. We review the epidemiology of invasive candidiasis in non-immunocompromised, critically ill patients with special emphasis on disease trends over time, pathophysiology, diagnostic approach, risk factors, and impact. Recent epidemiological data suggesting that the emergence of non-albicans candida strains with reduced susceptibility to azoles, previously linked to the use of new antifungals for empiric and prophylactic therapy in immunocompromised patients, may not have occurred in the critically ill. Management of invasive candidiasis in these patients will be addressed in the December issue of The Lancet Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592598     DOI: 10.1016/s1473-3099(03)00801-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  204 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

2.  In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.

Authors:  Sharon C-A Chen; Chayanika Biswas; Robyn Bartley; Fred Widmer; Namfon Pantarat; Daniel Obando; Julianne T Djordjevic; David H Ellis; Katrina A Jolliffe; Tania C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

3.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

4.  Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

5.  Evaluation of Modified Laboratory Processes for Isolation of Bacteria and Fungi in Continuous Ambulatory Peritoneal Dialysis Patients with Peritonitis.

Authors:  Shahram Ahmadi; Syafinaz Amin-Nordin; Vasantha Kumari Neela; Rukman Awang Hamat; Bak Leong Goh; Lailatul Akmar Mat Nor; Ahmad Zaid Fattah Azman
Journal:  Perit Dial Int       Date:  2015-12       Impact factor: 1.756

6.  Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring.

Authors:  Indy Sandaradura; Jessica Wojciechowski; Deborah J E Marriott; Richard O Day; Sophie Stocker; Stephanie E Reuter
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

7.  Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients.

Authors:  Laurence Senn; Philippe Eggimann; Riadh Ksontini; Andres Pascual; Nicolas Demartines; Jacques Bille; Thierry Calandra; Oscar Marchetti
Journal:  Intensive Care Med       Date:  2009-01-27       Impact factor: 17.440

Review 8.  Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs.

Authors:  Günter Kampf; Axel Kramer
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  The Effectiveness of Voriconazole in Therapy of Candida glabrata's Biofilms Oral Infections and Its Influence on the Matrix Composition and Gene Expression.

Authors:  Célia F Rodrigues; Bruna Gonçalves; Maria Elisa Rodrigues; Sónia Silva; Joana Azeredo; Mariana Henriques
Journal:  Mycopathologia       Date:  2017-04-24       Impact factor: 2.574

10.  In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.

Authors:  Sheng-Yuan Ruan; Chen-Chen Chu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.